Download PDF

1. Company Snapshot

1.a. Company Description

Cardio Diagnostics Holdings, Inc.develops and commercializes epigenetics-based clinical tests for cardiovascular disease.It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test.


Cardio Diagnostics Holdings, Inc.was founded in 2017 and is based in Chicago, Illinois.

Show Full description

1.b. Last Insights on CDIO

Negative drivers behind Cardio Diagnostics Holdings' recent performance include the lack of recent earnings release, which may indicate a delay in financial reporting. Furthermore, the company's decision to implement a 1-for-30 reverse stock split in May 2025 may be perceived as a negative signal by investors. Additionally, the recent patent issuance in Japan, while a positive development, may not have had a significant impact on the company's short-term performance. The absence of recent positive news and the potential uncertainty surrounding the company's financial reporting may have contributed to the negative sentiment.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Cardio Diagnostics Receives Final Gapfill Payment Rates for AI-Driven Cardiovascular Tests from the Centers for Medicare and Medicaid Services (CMS)

Dec -03

Source: businesswire.com

Card image cap

Cardio Diagnostics Holdings, Inc. to Present Data Demonstrating PrecisionCHD's Ability to Detect INOCA and MINOCA at the American Heart Association Scientific Sessions

Nov -05

Source: businesswire.com

Card image cap

NCH Becomes First U.S. Hospital to Use AI That Detects Hidden Heart Attack Risk a Decade in Advance

Nov -05

Source: prnewswire.com

Card image cap

Cardio Diagnostics Holdings, Inc. and YMCA of East Tennessee Partner to Bring Heart Health Education and Advanced Testing to East Tennessee Community

Oct -28

Source: businesswire.com

Card image cap

Cardio Diagnostics Holdings, Inc. Expands Provider Network, Adding 15 New Provider Organizations From Across the United States

Oct -21

Source: businesswire.com

Card image cap

Cardio Diagnostics Receives Gapfill Payment Rates for AI-Driven Cardiovascular Tests from the Centers for Medicare and Medicaid Services (CMS)

Jul -22

Source: businesswire.com

Card image cap

Cardio Diagnostics Enters Into an Agreement with AGEPHA Pharma to Advance Precision Assessment and Management of Inflammation Associated with Coronary Heart Disease

Jul -08

Source: businesswire.com

Card image cap

Cardio Diagnostics Secures Japanese Patent for AI-Driven Cardiovascular Disease Detection Technology

Jun -10

Source: businesswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (0.00%)

6. Segments

Artificial Intelligence-driven DNA Biomarker Testing Technology

Expected Growth: 15.4%

Growing demand for personalized medicine, increasing prevalence of cardiovascular diseases, and advancements in AI technology drive the growth of Artificial Intelligence-driven DNA Biomarker Testing Technology.

7. Detailed Products

Epi+Genomic Testing

A comprehensive genomic testing platform that analyzes genetic data to identify genetic variations associated with cardiovascular disease.

Epi+Cardiac Risk Assessment

A machine learning-based algorithm that analyzes genomic and clinical data to predict cardiovascular risk.

Epi+Genomic Analytics

A cloud-based platform that provides advanced genomic analytics and reporting for researchers and clinicians.

Epi+Clinical Decision Support

A clinical decision support tool that provides personalized treatment recommendations based on genomic and clinical data.

8. Cardio Diagnostics Holdings, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Cardio Diagnostics Holdings, Inc. is medium due to the presence of alternative diagnostic tools and services that can replace the company's offerings.

Bargaining Power Of Customers

The bargaining power of customers is low due to the specialized nature of Cardio Diagnostics Holdings, Inc.'s products and services, which limits the ability of customers to negotiate prices.

Bargaining Power Of Suppliers

The bargaining power of suppliers is medium due to the presence of multiple suppliers of raw materials and components, which gives Cardio Diagnostics Holdings, Inc. some negotiating power.

Threat Of New Entrants

The threat of new entrants is high due to the growing demand for diagnostic services and the relatively low barriers to entry in the industry.

Intensity Of Rivalry

The intensity of rivalry is high due to the presence of several established players in the diagnostic services market, leading to intense competition for market share.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 29.89%
Debt Cost 30.20%
Equity Weight 70.11%
Equity Cost 30.20%
WACC 30.20%
Leverage 42.63%

11. Quality Control: Cardio Diagnostics Holdings, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Cardio Diagnostics Holdings

A-Score: 2.9/10

Value: 7.6

Growth: 4.1

Quality: 3.2

Yield: 0.0

Momentum: 2.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
HCW Biologics

A-Score: 2.8/10

Value: 8.0

Growth: 4.1

Quality: 4.9

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Sangamo Therapeutics

A-Score: 2.8/10

Value: 7.2

Growth: 3.3

Quality: 4.1

Yield: 0.0

Momentum: 2.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Eyenovia

A-Score: 2.6/10

Value: 7.6

Growth: 4.8

Quality: 3.3

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Gritstone bio

A-Score: 2.6/10

Value: 7.8

Growth: 4.8

Quality: 2.4

Yield: 0.0

Momentum: 0.5

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Orchestra BioMed

A-Score: 2.2/10

Value: 6.0

Growth: 2.9

Quality: 3.6

Yield: 0.0

Momentum: 0.0

Volatility: 0.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

3.65$

Current Price

3.65$

Potential

-0.00%

Expected Cash-Flows